



## Supplementary Figures



**Supplementary Figure S1. Immune response in glioblastoma patients according to progression following PD1 blockade [2,5].**

62 patients received anti-PD-1 following glioblastoma. n = 28 for Nivolumab (Zhao) and n = 34 for Pembrolizumab (Prins). Immune response is measured using CRI iAtlas.  $p < 0.05$ , Wilcoxon t-test.



**Supplementary Figure S2. Immunomodulatory molecule expression in glioblastoma patients according to progression following PD1 blockade [2,5].**

62 patients received anti-PD-1 following glioblastoma. n=28 for Nivolumab (Zhao) and n = 34 for Pembrolizumab (Prins). Immunomodulatory molecule expression is measured using CRI iAtlas.  $p < 0.05$ , Wilcoxon t-test.